LYCOS RETRIEVER 
Genetics: Interleukin Genetics
built 481 days ago
WALTHAM, Mass., Dec. 19 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. ILI announced today that Alticor Inc., through its subsidiary Pyxis Innovations Inc., has converted a total of $2,039,680 of debt into shares of the Company's common stock. The converted debt represents principal and accrued interest from Promissory Notes issued from October 2002 through January 2003 which were to mature on December 31, 2007. Under the terms of the Promissory Notes, the conversion price of $0.6392 resulted in the Company's issuance of 3,190,987 shares of common stock. Pyxis has previously agreed not to sell these shares prior to August 17, 2008.
Source:
WALTHAM, Mass., Aug. 3 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. ILI today announced that it will release its second quarter financial results on Thursday, August 9 after the market closes. The Company's management will host the conference call at 4:30 PM EDT to review Interleukin's 2007 second quarter financial results and provide management updates.
Source:
"Interleukin Genetics remains at the forefront of delivering consumers genetics-focused personalized healthcare," said James Weaver, Vice President at Alticor. "Today's announcement is further demonstration of our belief in the company's growth opportunities and our continued support as a strategic partner." Mr. Weaver is ... Chairman of the Board of Interleukin.
Source:
Under the terms of the agreement, ABG will pay Interleukin Genetics $1.2 million during 2008 for the research. Approximately $800,000 of unspent funding from prior research agreements with Alticor shall ... be credited against the costs incurred under this new agreement.
Source:
MORE ABOUT
Interleukin Genetics